Advanced search
Publication Cover
Expert Review of Pharmacoeconomics & Outcomes Research Volume 4, 2004 - Issue 5
Submit an article Journal homepage
36
Views
2
CrossRef citations to date
0
Altmetric
Review

Cost–utility of inhaled corticosteroids in patients with moderate-to-severe asthma

Monia Marchetti IRCCS Policlinico San Matteo, Laboratory of Medical Informatics, Viale Golgi 19, 27100 Pavia, Italy. [email protected]
,
Maria Cavallo University L Bocconi, Health Economic Department, CeRGAS, Viale Isonzo 23, 20135 Milano, Italy. [email protected]
,
Elena Annoni Chiesi Farmaceutici SPA, via Palermo 26/A, 43100 Parma, Italy. [email protected]
&
Simone Gerzeli University of Pavia, Department of Applied Statistics and Economics ‘Libero Lenti’, Strada Nuova, 27100 Pavia, Italy. [email protected]
Pages 549-564 | Published online: 09 Jan 2014

References

  • Bragger J, Bakke P, Eide GE, Johansen B, Andersen A, Gulsvik A. Long-term changes in adult asthma prevalence. Eur. Respir. J 21(3), 468–472 (2003).
  • De Marco R, Cerveri I, Bugiani M, Ferrari M, Verlato G. An undetected burden of asthma in Italy: the relationship between clinical and epidemiological diagnosis of asthma. Eur. Respir. J11(3), 599–605 (1998).
  • Viegi G, Pedreschi M, Baldacci S et al. Prevalence rates of respiratory symptoms and diseases in general population samples of North and Central Italy. Int. j TUberc. Lung. Dis. 3(11), 1034–1042 (1999).
  • European Community Respiratory Health Survey. Variations in the prevalence of respiratory symptoms, self-reported asthma attacks, and use of asthma medication in the European Community Respiratory Health Survey (ECRHS). Eur. Respir. 9(4), 687–695 (1996).
  • Berm P, Gianfrate E Ii costa dell'asma in Italia. G. Farmacoeconomia 3, 57–64 (1999).
  • De Carli G, Dal Negro R, Recchia G et al. Asma bronchiale: considerazioni farmacoeconomiche. Alpe-Adria-Pannonia Congress, Trieste, Italy (1992).
  • National Heart, Lung and Blood Institute. Guidelines for the diagnosis and management of asthma. NIH Publication No 97–4051 (1997).
  • Adams N, Bestall JM, Jones PW. Fluticasone versus beclomethasone or budesonide for chronic asthma. Cochrane Database Syst. Rev. 1, CD002310 (2002).
  • Adams N, Bestall JM, Jones PW. Inhaled beclomethasone versus budesonide for chronic asthma. Cochrane Database Syst. Rev 1, CD003530 (2002).
  • Osborne ML, Vollmer WM, Pedula KL et al. Lack of correlation of symptoms with specialist-assessed long-term asthma severity. Chest. 115(1), 85–91 (1999).
  • Zillich AJ, Blumenschein K, Johannesson M, Freeman E Assessment of the relationship between measures of disease severity, quality of life, and willingness to pay in asthma. PharmacoEconomics 20(4), 257–265 (2002).
  • Revicki DA, Leidy NK, Brennan-Diemer F, Sorensen S, Togias A. Integrating patient preferences into health outcomes assessment. The Multiattribute Asthma Symptom Utility Index. Chest 114(4), 998–1007 (1998).
  • ••Validates a symptom assessment scale foruse as a preference-based outcome.
  • Sonnenberg FA, Beck JR. Markov models in medical decision making: a practical guide. Med. Dec. Making 13(4), 322–338 (1993).
  • Juniper EF, Price DB, Chir MB et al. Clinically important improvements in asthma-specific quality of life, but no difference in conventional clinical indexes in patients changed from conventional beclomethasone dipropionate to approximately half the dose of extrafine beclomethasone dipropionate. Chest 121 (6), 1824–1832 (2002).
  • Israel E, Cohn J, Dube L, Drazen JM. Effect of treatment with zileuton, a 5-lipoxygenase inhibitor, in patients with asthma. A randomized controlled trial. Zileuton Clinical Trial Group. JAMA 275(12), 931–936 (1996).
  • Hoskins G, McCowan C, Neville RG et al. Risk factors and costs associated with an asthma attack. Thorax 55 (1), 19–24 (2000).
  • Price D, Haughney J, Duerden M, Nicholls C, Moseley C. The cost-effectiveness of CFC-free beclomethasone diproprionate in the treatment of chronic asthma. A cost model based on a 1-year pragmatic, randomised clinical study. PharmacoEconomics 20(10), 653–664 (2002).
  • Fireman P, Prenner BM, Vincken W et al Long-term safety and efficacy of a chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosol. Ann. Allergy Asthma Immunol 86(5), 557–565 (2001).
  • •• Estimates 12-month clinical outcomes of maintenance treatment with beclomethasone-extrafine versus beclomethasone.
  • Worth H, Muir JF, Pieters WR. Comparison of hydrofluoroalkane-beclometasone diproprionate AutohalerTM with Budesonide TurbohalerTM in asthma control. Respiration 68(5), 517–526 (2001).
  • Aubier M, Wettenger R, Gans SJM. Efficacy of EF-beclomethasone diproprionate extra-fine aerosol (800 pg day-1) versus EF-fluticasone proprionate (1000 pg day 1) in patients with asthma. Respir. Med. 95(3), 212–220 (2001).
  • Reichel W, Dahl R, Ringdal N et al Extrafine beclomethasone diproprionate breath-actuated inhaler (400 pg/day) versus budesonide dry powder inhaler (800 pg/ day) in asthma. Int. J. Clin. Pract. 55(2), 100–106 (2001).
  • Fairfax A, Hall I, Spelman R. A randomized, double-blind comparison of beclomethasone dipropionate extrafine aerosol and fluticasone proprionate. Ann. Allergy Asthma Immunol 86(5), 575–582 (2001).
  • Frieri M, Therattil J, Dellavecchia D et al. A preliminary retrospective treatment and pharmacoeconomic analysis of asthma care provided by allergists, immunologists, and primary care physicians in a teaching hospital. J Asthma 39(5), 405–412 (2002).
  • Decreto Ministeriale 30 Giugno 1997, Revisione delle tariffe di cui al Decreto Ministeriale 15 Aprile 1994 e Decreto Ministeriale 14 Dicembre 1994.
  • Prestazioni di assistenza specialistica ambulatoriale erogabili nell'ambito del SSN e relative tariffe. DM 22/7/96 Gazzetta Ufficiale 216,14/9/1996. Supplemento ordinario.
  • Tarricone R, Martelli E, Parazzini F et al. Economic evaluation analysis of nimesulide vs. diclofenac in the treatment of osteoarthritis in France, Italy and Spain. Clin. Drug Invest. 21,435–464 (2001).
  • Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank Mem. Fund. Q. Health Soc. 60(3), 429–462 (1982).
  • Ungar WJ, Coyte PC and the Pharmacy Medication Monitoring Program Advisory Board. Measuring productivity loss days in asthma patients. Health Econ. 9(1), 37–46 (2000).
  • Banca d'Italia. Supplementi al bollettino statistico: I bilanci delle famiglie italiane nell'anno 1998.22,9-10 (2000).
  • Godard P, Chanez P, Siraudin L, Nicoloyannis N, Duru G. Costs of asthma are correlated with severity: a 1-yr prospective study. Eur. Respir. 1 19(1), 61–67 (2002).
  • Dal Negro R, Berto P, Tornella S, Quareni L on behalf of the GOLD study group. Cost-of-illness of lung disease in the
  • Terzano C, Berto P, Cremonesi G, Pulli C. Cost-minimization analysis of two different inhaled steroids in persistent bronchial asthma. Eur. Resp. J. 20 (30), S1902 (2002).
  • Cote J, Cartier A, Robichaud P et al Influence on asthma morbidity of asthma education programs based on self-management plans following treatment optimization. Am. J Respli: Crit. Care. Med. 155(5), 1509–1514 (1997).
  • Kuntz KM, Kitch BT, Fuhlbrigge AL, Paltiel AD, Weiss ST. A novel approach to defining the relationship between lung function and symptom status in asthma. J. Clin. Epidemiol 55(1), 11–18 (2002).
  • ••Estimates the relationship between FEViand asthma symptom scores.
  • Schulpher M. Using economic evaluations to reduce the burden of asthma and chronic obstructive pulmonary disease. PharmacoEconomics19\(Suppl. 2), 21–25 (2001).
  • Price MJ, Briggs AH. Development of an economic model to assess the cost-effectiveness of asthma management strategies. PharmacoEconomics 20(3), 183–194 (2002).
  • ••Estimates the cost—utility of fluticasonepropionate with/without salmeterol based on data from a 12-week randomized trial.
  • Stempel DA, Standford RH, Thwaites R, Price M. Cost-efficacy comparison of inhaled fluticasone propionate and budesonide in the treatment of asthma. Clin. Ther. 22(12), 1562–1574 (2000).
  • Malone DC, Luskin AT. Hydrofluoroalkane-134a beclomethasone as a dominant economic asthma therapy. Respir. Med. 97(12), 1269–1276 (2003).
  • •• Prospective estimate of 12-month cost per symptom-free day of beclomethasone-extrafine versus beclomethasone.
  • Malone DC, Armstrong EP. Economic burden of asthma: implications for outcomes and cost-effectiveness analyses. Expert. Rev Pharmacoeconomics Outcomes. Res. 1,177–186 (2001).
  • Paltiel AD, Fuhlbrigge AL, Kitch BT et al. Cost-effectiveness of inhaled corticosteroids in adults with mild-to-moderate asthma: results from the Asthma Policy Model. J. Allergy Clin. Immunol 108(1), 39–46 (2001).
  • ••Estimates lifetime cost and quality of lifeof patients receiving inhaled corticosteroids.
  • Combescure C, Chanez P, Saint-Pierre P, Daufes J-P, Proudhon H, Godard P on behalf of the Association pour la Recherche en Intelligence ArtificielleTM (ARIA) group. Assessment of variation in control of asthma over time. Eur. Respir. J. 22(2), 298–304 (2003).
  • Thomas M, Haughney J, Price D. Cost effectiveness of asthma management strategies. PharmacoEconomics 20(11), 789 (2002).
  • Ungar WJ, Coyte PC. Measuring productivity loss days in asthma patients. The Pharmacy Medication Monitoring Program and Advisory Board. Health. Econ. 9(1), 37–46 (2000).
  • Sculpher M, Drummond M, Buxton M. The iterative use of economic evaluation as part of the process of health technology assessment. J. Health. Serv. Res. Policy 2(1), 26–30 (1997).
  • Evans C, Crawford B. Expert judgment in pharmacoeconomic studies. Guidance and future use. PharmacoEconomics 17(6), 545–553 (2000).
  • Price D, Thomas M, Mitchell G, Miziol C, Featherstone R. Improvement of asthma control with a breath-actuated pressurized metered dose inhaler (Bai), a prescribing claims study of 5556 patients using a traditional pressurised mdetered dose inhaler (MD() or a breath-actuated device. Respir. Med. 97, 12–19 (2003).
  • Vandentorren S, Baldi I, Annesi Maesano I et al. Long-term mortality among adults with or without asthma in the PAARC study. Eur. Respir. J. 21(3), 462–467 (2003).

Website

  • Ministry of Health www.sanita.it (Accessed September 2004)

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.